{"filings":[{"id":91971,"accession_number":"0001294133-26-000014","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q1 revenue up 3.4% to $85.1M; net loss widens to $8.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $8.3M vs $6.2M loss in Q1 2025; adjusted net loss $4.0M vs $2.9M.","Adjusted EBITDA turned negative at -$1.4M vs +$0.04M a year ago on R&D investments.","Cash and securities $111.5M, no debt; $30M share repurchase authorized, $1.9M executed.","Introduced Aurora CPAP masks in U.S. and launched Rove 6 POC in Brazil.","Appointed Jason Richardson as CFO and Dominic Hulton as CMO; reiterated full-year 2026 revenue guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":85109000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91970,"accession_number":"0001193125-26-143703","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Vafa Jamali to board, enters cooperation agreement with Kent Lake","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vafa Jamali appointed as independent Class I director effective June 15, 2026 or 2026 annual meeting.","Jamali previously CEO of ZimVie and SVP/President of Medtronic's $3B Respiratory, GI & Informatics division.","Cooperation agreement with Kent Lake includes standstill, voting commitment, and 4.99% ownership cap.","Jamali to receive $180k initial RSU grant, plus annual cash fees of $60k for board and committee roles.","Kent Lake agreed to vote shares per board recommendations except on extraordinary transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102412,"accession_number":"0001193125-26-131855","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen names Jason Richardson CFO, appoints CMO and VP Sales; reaffirms 2026 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Richardson appointed CFO effective April 6, 2026; previously CFO of Baxter's Health System & Technologies segment.","Michael Bourque steps down as CFO on April 6, remains Senior Advisor through June 30, 2026.","Dominic Hulton appointed CMO effective April 1, 2026; previously VP International Marketing at Insulet.","Corey Moritz appointed VP U.S. Business to Business Sales, started March 9; formerly CCO at Rhythm Healthcare.","Company reaffirms Q1 and full year 2026 financial outlook provided on February 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102411,"accession_number":"0001193125-26-066968","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inogen reports FY2025 revenue $348.7M (+3.9%); net loss narrows to $22.7M; first positive adj. EBITDA in four years","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $348.7M (+3.9% YoY); net loss $22.7M improved from $35.9M loss in 2024.","Adjusted EBITDA turned positive at $2.7M (vs -$9.5M in 2024); Q4 adj. EBITDA -$1.7M improved from -$3.6M.","Cash and equivalents $120.9M with zero debt; Board authorized $30M share repurchase program through Dec 2027.","International POC sales grew 18.4% in 2025; introduced new products Voxi 5, Aurora CPAP masks, Simeox airway clearance.","Total gross margin 44.2% in 2025 vs 46.1% in 2024 due to channel mix."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":348668000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102410,"accession_number":"0001193125-26-009878","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen prelim Q4 rev ~$82M (+2% YoY); FY25 rev ~$349M (+4%); order delays into H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 preliminary revenue ~$82M, up ~2% YoY; full-year 2025 ~$349M, up ~4% YoY.","Company expects to achieve positive Adjusted EBITDA for full-year 2025.","Shift in timing of a few large customer orders from Q4 2025 to H1 2026 caused disappointment.","Full-year highlights: launches of Voxi 5 concentrator and Aurora Masks in U.S.; revenue growth and progress toward profitability.","Full Q4/FY2025 results and 2026 guidance to be announced on February 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":348668000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118685,"accession_number":"0001193125-25-265750","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q3 revenue $92.4M (+4% YoY); adj. EBITDA positive $2.3M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $92.4M, up 4% YoY; seventh consecutive quarter of mid-single-digit growth.","GAAP net loss $5.3M vs $6.0M loss; adjusted net loss $0.5M vs $2.6M loss.","Adjusted EBITDA $2.3M (third consecutive positive quarter); full-year adj. EBITDA guidance raised to ~$2M.","Cash $124.5M, no debt; initiated limited U.S. release of Simeox airway clearance device.","Gross margin 44.7% down from 46.5% due to higher B2B sales mix."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":266947000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135190,"accession_number":"0000950170-25-105080","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q2 2025 revenue $92.3M (+4% YoY); raises full-year revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $92.3M, up 4% YoY; sixth consecutive quarter of mid-single-digit growth.","GAAP net loss $4.2M; adjusted net loss $0.7M, improved from $1.6M loss a year ago.","Adjusted EBITDA positive $2.1M, second consecutive quarter; operating cash flow $4.4M.","Cash and marketable securities $123.7M, no debt outstanding.","Raising full-year 2025 revenue expectations; new product Voxi 5 introduced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":174557000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135189,"accession_number":"0000950170-25-099624","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inogen appoints Mary Wright as CAO, designates EVP Yi Boyer as executive officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Yi Boyer designated as executive officer and Section 16 officer effective July 28, 2025; she serves as EVP, Enterprise Enablement and CHRO.","Mary Wright appointed Chief Accounting Officer effective July 28, 2025; CFO Michael Bourque remains principal accounting officer.","Yi Boyer receives $430K base salary, target bonus 50% of base; Wright receives $312K base, target bonus 35%.","Both appointments are internal promotions; no changes to board or other executive roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152166,"accession_number":"0000950170-25-074437","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Inogen stockholders approve 2023 equity incentive plan amendment increasing share reserve by 750,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["20.9M shares (77.87% of outstanding) present at the annual meeting.","Amended and Restated 2023 Equity Incentive Plan approved, adding 750,000 shares to the reserve.","Class II directors Kevin King, Mary Kay Ladone, and Kevin R.M. Smith elected.","Deloitte & Touche LLP ratified as independent auditor for fiscal year 2025.","Advisory vote on executive compensation passed with 16.7M votes for, 1.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152165,"accession_number":"0000950170-25-065644","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q1 2025 revenue $82.3M (+5.5% YoY); adjusted EBITDA turns positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $82.3M, up 5.5% YoY (7.1% constant currency) on higher B2B demand.","GAAP net loss narrowed to $6.2M from $14.6M; adjusted net loss $2.9M vs $10.4M.","Adjusted EBITDA improved to positive $0.04M from negative $7.6M in prior year.","Cash $122.5M, no debt; operating expense down 13.1% to $44.0M on lower consulting."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":82280000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170993,"accession_number":"0000950170-25-026636","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q4 revenue up 5.5% to $80.1M; full-year revenue up 6.4%; operating loss narrows significantly","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $80.1M (+5.5% YoY); gross margin 45.3% (vs 37.1% YoY) on lower raw material costs and efficiencies.","Q4 GAAP net loss $9.8M improved from $26.6M; adjusted net loss $5.8M; adjusted EBITDA negative $3.6M.","Full-year 2024 revenue $335.7M (+6.4%); operating loss $42.5M (improved from $109.4M); cash $117.4M, no debt.","Company provides 2025 growth outlook; announced strategic collaboration with Yuwell to expand product portfolio and global reach.","Pending U.S. introduction of Simeox airway clearance therapy highlighted as key future growth driver."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":335705000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170992,"accession_number":"0000950170-25-012334","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Mira Kirti Sahney to board; Tom West retires effective Jan 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mira Sahney appointed to Inogen board effective Jan 31, 2025 as Class III director; term expires at 2026 annual meeting.","Tom West resigned from board and committees effective Jan 30, 2025, not due to any disagreement with Inogen.","Sahney brings Medtronic, Hyalex Orthopaedics, Smith+Nephew, and Myomo experience; joins Nominating/Governance and Compliance committees.","Initial restricted stock unit award of 9,112 shares vesting May 14, 2025; annual cash retainer $45,000 plus committee fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170991,"accession_number":"0000950170-25-008986","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Inogen partners with Yuwell; receives ~$27.2M investment for 9.9% stake at $10.36/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Strategic collaboration with Jiangsu Yuyue to distribute respiratory products in US/Europe and expand into China.","Yuwell affiliate to purchase 2,626,425 shares at $10.36/share, totaling ~$27.2M (9.9% equity).","Closing expected in Q1 2025, subject to customary conditions; registration rights granted after 180 days.","Collaboration aims to broaden Inogen's product portfolio, R&D pipeline, and geographic reach.","Press release issued Jan 26, 2025; agreements effective immediately, equity purchase to close Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170990,"accession_number":"0000950170-25-004824","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen reports prelim Q4 rev $79M-$80M (+4-5%); FY24 rev $334.5M-$335.5M (+6%), beats guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 preliminary revenue of $79M-$80M, up 4-5% YoY.","Full-year 2024 preliminary revenue of $334.5M-$335.5M, up 6% YoY, exceeding prior guidance of $329M-$331M.","Driven by strong double-digit B2B revenue growth; DTC revenue stabilization ongoing.","Launched Rove 4 and received FDA clearance for SIMEOX 200 during Q4.","Official Q4/FY results and conference call scheduled for Feb 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":335705000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187969,"accession_number":"0000950170-24-140955","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inogen receives FDA 510(k) clearance for SIMEOX 200, triggering $13M milestone payment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared SIMEOX 200 for airway clearance and bronchial drainage in patients with chronic lung diseases.","Clearance triggers $13M cash earnout payment to Physio-Assist sellers under July 2023 purchase agreement.","Device targets mucus hypersecretion in Bronchiectasis, COPD, Cystic Fibrosis, and Primary Ciliary Dyskinesia.","Inogen plans limited U.S. launch in 2025 via existing HCP, B2B, and direct-to-patient channels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187968,"accession_number":"0000950170-24-123329","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q3 revenue up 5.8% to $88.8M; adjusted EBITDA turns positive $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $88.8M (+5.8% YoY) driven by business-to-business gains; direct-to-consumer and rental revenue fell.","GAAP net loss narrowed to $6.0M from $45.7M; adjusted net loss $2.6M from $8.5M.","Adjusted EBITDA positive $0.5M vs negative $5.5M in Q3 2023; gross margin improved to 46.5% from 40.2%.","Operating expenses fell 39% to $49.1M (prior year included goodwill impairment).","Cash $124.3M, no debt; CEO cites progress toward sustainable profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":255624000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204479,"accession_number":"0000950170-24-091800","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q2 revenue up 6.1% to $88.8M; net loss narrows to $5.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $88.8M (+6.1% YoY) driven by international and domestic B2B sales.","GAAP net loss -$5.6M vs -$9.8M YoY; adjusted net loss -$1.6M vs -$5.8M.","Gross margin improved to 48.1% from 40.7% YoY on lower component costs.","Adjusted EBITDA turned positive at $1.3M from -$3.2M YoY.","Cash & equivalents $121.2M; no debt outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":166790000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204478,"accession_number":"0000950170-24-088682","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inogen EVP & General Counsel Jason Somer separates effective July 19; enters transition agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation date July 19, 2024; role as EVP and General Counsel ended.","Transition agreement signed July 26 provides 12 months base salary continuation ($13,269.23 per pay period) and COBRA reimbursement for up to 12 months.","All unvested equity awards forfeited; vested options remain exercisable per stock agreements.","Employee agrees to cooperate for one year and releases all claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204477,"accession_number":"0000950170-24-081526","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Kevin Smith as GC and EVP Business Development; Jason Somer departs July 19","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Somer, EVP, General Counsel & Secretary, to separate from Inogen on July 19, 2024.","Kevin P. Smith appointed as EVP, Business Development, General Counsel & Secretary, effective July 22, 2024.","Smith will receive base salary of $420,000, target bonus of 50%, and $500,000 in RSUs vesting over 3 years.","Smith previously served as GC and EVP Business Development at Sirtex Medical since 2018.","Separation and appointment are part of leadership transition; Smith's employment agreement filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221278,"accession_number":"0000950170-24-070900","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Inogen stockholders approve amended 2023 equity plan, elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended & Restated 2023 Equity Incentive Plan: 14,014,481 for, 2,868,882 against, 79,455 abstentions (2,335,280 broker non-votes).","Plan increased authorized shares by 1,200,000 and removed 'liberal' share counting for stock options/SARs.","Class I directors elected: Elizabeth Mora (8,127,945 for, 8,834,873 withheld) and Heather Rider (10,805,031 for, 6,157,787 withheld).","Ratification of Deloitte & Touche as auditor for FY2024 approved (19,159,675 for, 135,625 against).","Advisory vote on executive compensation passed: 15,676,226 for, 1,214,214 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221277,"accession_number":"0000950170-24-060589","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inogen CMO Stanislav Glezer departs; severance includes 12-month salary & COBRA","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Stanislav Glezer separated as EVP R&D and Chief Medical Officer effective April 11, 2024.","Severance: 12 months base salary of $505,000 (26 pay periods) and COBRA premium reimbursement for 12 months.","Unvested equity awards forfeited; vested stock options remain exercisable per plan terms.","No annual bonus owed; tuition repayment for CEO program waived.","Separation agreement includes standard release of claims and confidentiality obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221276,"accession_number":"0000950170-24-054483","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q1 revenue up 8.1% to $78M; net loss narrows from $20.3M to $14.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $78.0M (+8.1% YoY) driven by higher international and domestic B2B sales.","GAAP net loss $14.6M vs $20.3M YoY; adjusted net loss $10.4M vs $14.5M.","Gross margin 44.1% up from 42.6%, helped by lower component costs.","Operating expenses down 3.8% to $50.6M; cash $119.8M, no debt outstanding.","CEO cites solid start; focused on revenue growth, profitability, and innovation pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":78025000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221275,"accession_number":"0000950170-24-044416","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inogen EVP R&D & Chief Medical Officer Stanislav Glezer to depart by May 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mutual separation of Dr. Stanislav Glezer, EVP R&D and Chief Medical Officer, effective on or before May 3, 2024.","Company expects to enter a separation agreement with benefits consistent with his existing 2021 severance agreement.","No successor named; disclosure of separation agreement terms to be filed later.","Glezer was responsible for R&D and clinical strategy; departure leaves a key leadership gap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240835,"accession_number":"0000950170-24-021113","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inogen Q4 revenue $75.9M (-14% YoY); FY net loss $102.4M, adj EBITDA -$37.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $75.9M vs $88.1M YoY; full-year revenue $315.7M vs $377.2M in 2022.","Q4 GAAP net loss $26.6M vs $56.6M loss YoY; adjusted net loss $19.4M vs $13.0M loss.","Full-year GAAP net loss $102.4M vs $83.8M loss; adjusted EBITDA -$37.8M vs -$13.5M.","Cash, equivalents and marketable securities $128.5M, no debt; gross margin improved to 37.1% in Q4.","New CCO Grégoire Ramade and CFO Michael Bourque appointed; focus on Physio-Assist U.S. launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":315660000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240834,"accession_number":"0000950170-24-006969","cik":1294133,"company_name":"Inogen Inc","ticker":"INGN","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inogen appoints Michael Bourque as CFO effective March 4, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Bourque appointed EVP, CFO and Treasurer; succeeds interim CFO Mike Sergesketter who stays for transition.","Annual base salary of $425,000; target bonus of 60% of base; $100,000 sign-on bonus (pro-rata clawback for 2 years).","Equity award of 150,000 RSUs/PSUs (75k time-based, 75k performance-based; up to 150k PSUs for overachievement).","Severance: 12 months base salary + COBRA if terminated without cause; 24 months if within change of control period.","Bourque previously CFO of Chase Corporation (NYSE:CCF); also CFO of Analogic and VP Finance at Axcelis Technologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178962550.47872344,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}